GSE110741
Novel Alzheimer risk genes determine the microglia response to amyloid-ß but not to TAU pathology
Polygenic risk scores have identified that genetic variants without genome-wide significance still add to the genetic risk of developing Alzheimer's disease (AD). Whether and how subthreshold risk loci translate into relevant disease pathways, is unknown. We investigate here the involvement of AD risk variants in the transcriptional responses of two mouse models: APPswe/PS1L166P and Thy-TAU22. A unique gene expression module, highly enriched for AD risk genes, is specifically responsive to Aß but not TAU pathology. We identify in this module 7 established AD risk genes (APOE, CLU, INPP5D, CD33, PLCG2, SPI1 and FCER1G) and 11 AD GWAS genes below the genome-wide significance threshold (GPC2, TREML2, SYK, GRN, SLC2A5, SAMSN1, PYDC1, HEXB, RRBP1, LYN and BLNK), that become significantly upregulated when exposed to Aß. Single microglia sequencing confirms that Aß, not TAU, pathology induces marked transcriptional changes in microglia, including increased proportions of activated microglia. We conclude that genetic risk of AD functionally translates into different microglia pathway responses to Aß pathology, placing AD genetic risk downstream of the amyloid pathway but upstream of TAU pathology. Overall design: mRNAseq on 96 biological samples (mouse hippocampus), n=12 per experimental group, examining APPswe/PSEN1L166P and Thy-TAU22 mice and their respective WT littermates, at 4 and 10 months of age (8 groups in total)